Claims for Patent: 10,512,684

Summary for Patent: 10,512,684

Title:	Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin
Abstract:	Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a flagellin, and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increased T-cell and antibody mediated immune responses specific for the heterologous disease-associated antigen when administered to a subject, e.g. a human subject, and related methods and uses.
Inventor(s):	Lauterbach; Henning (Eching, DE), Hochrein; Hubertus (Munich, DE), Sanos; Stephanie (Munich, DE)
Assignee:	Bavarian Nordic A/S (Kvistgaard, DK)
Application Number:	15/512,820
Patent Claims:	1. An immunogenic composition comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a flagellin and further comprising a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces: a) increased T-cell and/or B-cell immune responses specific for the heterologous disease-associated antigen, and b) increased innate immune responses when administered to a subject as compared to T-cell and/or B-cell immune responses specific for the heterologous disease-associated antigen and innate immune responses induced by administration of a recombinant MVA comprising a nucleic acid sequence encoding a heterologous disease-associated antigen but not a nucleic acid sequence encoding a flagellin; wherein said recombinant modified vaccinia virus Ankara (MVA) is capable of reproductive replication in chicken embryo fibroblasts. 2. The immunogenic composition of claim 1, wherein the increased T-cell immune response comprises greater numbers of cytotoxic T-cells (CTLs) specific for the heterologous disease-associated antigen. 3. The immunogenic composition of claim 1, wherein the nucleic acid sequence encodes a flagellin having at least 95% amino acid sequence identity to SEQ ID NO:1. 4. The immunogenic composition of claim 3, wherein the nucleic acid sequence encodes a flagellin having the amino acid sequence of SEQ ID NO:1. 5. The immunogenic composition of claim 1, further comprising a pharmaceutically acceptable carrier. 6. The immunogenic composition of claim 1, wherein the disease-associated antigen is an infectious disease antigen or a tumor-associated antigen. 7. The immunogenic composition of claim 6, wherein the disease-associated antigen is an infectious disease antigen selected from a viral antigen, a bacterial antigen, a fungal antigen, and a parasite antigen. 8. The immunogenic composition of claim 7, wherein the infectious disease antigen is a viral antigen. 9. The immunogenic composition of claim 8, wherein the viral antigen is derived from a virus selected from the group consisting of adenovirus, Arbovirus, Astrovirus, Coronavirus, Coxsackievirus, Crimean-Congo hemorrhagic fever virus, cytomegalovirus (CMV), dengue virus, Ebola virus, Epstein-Barr virus (EBV), Foot-and-mouth disease virus, Guanarito virus, Hendra virus, herpes simplex virus-type 1 (HSV-1), herpes simplex virus-type 2 (HSV-2), human herpesvirus-type 6 (HHV-6), human herpesvirus-type 8 (HHV-8), hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), hepatitis E virus (HEV), human immunodeficiency virus (HIV), influenza virus, Japanese encephalitis virus, Junin virus, Lassa virus, Machupo virus, Marburg virus, measles virus, human metapneumovirus, Molluscum contagiosum virus, mumps virus, Newcastle disease virus, Nipha virus, Norovirus, Norwalk virus, human papillomavirus (HPV), parainfluenza virus, parvovirus, poliovirus, rabies virus, respiratory syncytial virus (RSV), rhinovirus, rotavirus, rubella virus, Sabia virus, severe acute respiratory syndrome virus (SARS), varicella zoster virus, variola virus, West Nile virus, and yellow fever virus. 10. A method of inducing an antigen-specific immune response to a disease-associated antigen in a subject comprising administering to the subject an immunogenic composition comprising a nucleic acid sequence encoding a flagellin and further comprising a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces: a) increased T-cell and/or B-cell immune responses specific for the heterologous disease-associated antigen, and b) increased innate immune responses as compared to T-cell and/or B-cell immune responses specific for the heterologous disease-associated antigen and innate immune responses induced by administration of a recombinant MVA comprising a nucleic acid sequence encoding a heterologous disease-associated antigen but not a nucleic acid sequence encoding a flagellin; wherein said recombinant modified vaccinia virus Ankara (MVA) is capable of reproductive replication in chicken embryo fibroblasts. 11. The method of claim 10, wherein the increased T-cell immune response comprises greater numbers of cytotoxic T-cells (CTLs) specific for the heterologous disease-associated antigen. 12. The method of claim 10, wherein the nucleic acid sequence encodes a flagellin having at least 95% amino acid sequence identity to SEQ ID NO:1. 13. The method of claim 12, wherein the nucleic acid sequence encodes a flagellin having the amino acid sequence of SEQ ID NO:1. 14. The method of claim 10, wherein the disease-associated antigen is an infectious disease antigen or a tumor-associated antigen. 15. The method of claim 14, wherein the disease-associated antigen is an infectious disease antigen selected from a viral antigen, a bacterial antigen, a fungal antigen, and a parasite antigen. 16. The method of claim 15, wherein the infectious disease antigen is a viral antigen. 17. The method of claim 16, wherein the viral antigen is derived from a virus selected from the group consisting of adenovirus, Arbovirus, Astrovirus, Coronavirus, Coxsackievirus, Crimean-Congo hemorrhagic fever virus, cytomegalovirus (CMV), dengue virus, Ebola virus, Epstein-Barr virus (EBV), Foot-and-mouth disease virus, Guanarito virus, Hendra virus, herpes simplex virus-type 1 (HSV-1), herpes simplex virus-type 2 (HSV-2), human herpesvirus-type 6 (HHV-6), human herpesvirus-type 8 (HHV-8), hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), hepatitis E virus (HEV), human immunodeficiency virus (HIV), influenza virus, Japanese encephalitis virus, Junin virus, Lassa virus, Machupo virus, Marburg virus, measles virus, human metapneumovirus, Molluscum contagiosum virus, mumps virus, Newcastle disease virus, Nipha virus, Norovirus, Norwalk virus, human papillomavirus HPV), parainfluenza virus, parvovirus, poliovirus, rabies virus, respiratory syncytial virus (RSV), rhinovirus, rotavirus, rubella virus, Sabia virus, severe acute respiratory syndrome virus (SARS), varicella zoster virus, variola virus, West Nile virus, and yellow fever virus. 18. The method of claim 15, wherein the infectious disease antigen is a bacterial antigen. 19. The method of claim 18, wherein the bacterial antigen is derived from a bacterium selected from the group consisting of Bacillus anthracis, Bordetella pertussis, Borrelia burgdorferi; Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Burkholderia mallei, Burkholderia pseudomallei, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium diptheriae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Francisella tularensis, Haemophilus influenza, Helicobacter pylori, Legionella pneumophila, Leptospira interrogans, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitides, Pseudomonas aeruginosa, Rickettsia rickettsia, Salmonella typhi, Salmonella typhimurium, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Treponema pallidum, Vibrio cholerae, and Yersinia pestis. 20. The method of claim 15, wherein the fungal antigen is derived from a fungus selected from the group consisting of Aspergillus clavatus, Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger, Aspergillus terreus, Blastomyces dermatitidis, Candida albicans, Candida dubliniensis, Candida glabrata, Candida parapsilosis, Candida rugosa, Candida tropicalis, Cryptococcus albidus, Cryptococcus gattii, Cryptococcus laurentii, Cryptococcus neoformans, Ilistoplasma capsulatum, Microsporum canis, Pneumocystis carinii, Pneumocystis jirovecii, Sporothrix schenckii, Stachbotrys chartarum, Tinea barbae, Tinea captitis, Tinea corporis, Tinea cruris, Tinea faciei, Tinea incognito, Tinea nigra, Tinea versicolor, Trichophyton rubrum and Trichophyton tonsurans. 21. The method of claim 14, wherein the disease-associated antigen is a tumor-associated antigen. 22. The method of claim 21, wherein the tumor associated antigen is selected from the group consisting of 5-.alpha.-reductase, .alpha.-fetoprotein ("AFP"), AM-1, APC, April, B melanoma antigen gene (BAGE), .beta.-catenin, Bcl12, bcr-abl, Brachyury, CA-125, caspase-8 (CASP-8, also known as FLICE), Cathepsins, CD19, CD20, CD21/complement receptor 2 (CR2), CD22/BL-CAM, CD23/Fc.epsilon.RII, CD33, CD35/complement receptor 1 (CR1), CD44/PGP-1, CD45/leucocyte common antigen (LCA), CD46/membrane cofactor protein (MCP), CD52/CAMPATH-1, CD55/decay accelerating factor (DAF), CD59/protectin, CDC27, CDK4, carcinoembryonic antigen (CEA), c-myc, cyclooxygenase-2 (cox-2), deleted in colorectal cancer gene (DCC), DcR3, E6/E7, CGFR, EMBP, Dna78, farnesyl transferase, fibroblast growth factor-8a (FGF8a), fibroblast growth factor-8b (FGF8b), FLK-1/KDR, folic acid receptor, G250, G melanoma antigen gene family (GAGE-family), gastrin 17, gastrin-releasing hormone, ganglioside 2 (GD2)/ganglioside 3 (GD3)/ganglioside-monosialic acid-2 (GM2), gonadotropin releasing hormone (GnRH), UDP-GlcNAc:R1Man(.alpha.1-6)R2 [GlcNAc to Man(.alpha.1-6)] .beta.1,6-N-acetylglucosaminyltransferase V (GnT V), GP1, gp100/Pme117, gp-100-in4, gp15, gp75/tyrosine-related protein-1 (gp75/TRP-1), human chorionic gonadotropin (hCG), heparanase, Her2/neu, human mammary tumor virus (HMTV), 70 kiloDalton heat-shock protein (HSP70), human telomerase reverse transcriptase (hTERT), insulin-like growth factor receptor-1 (IGFR-1), interleukin-13 receptor (IL-13R), inducible nitric oxide synthase (iNOS), Ki67, KIAA0205, K-ras, H-ras, N-ras, KSA, LKLR-FUT, melanoma antigen-encoding gene 1 (MAGE-1), melanoma antigen-encoding gene 2 (MAGE-2), melanoma antigen-encoding gene 3 (MAGE-3), melanoma antigen-encoding gene 4 (MAGE-4), mammaglobin, MAP17, Melan-A/melanoma antigen recognized by T-cells-1 (MART-1), mesothelin, MIC MT-MMPs, mucin, testes-specific antigen NY-ESO-1, osteonectin, p15, P170/MDR1, p53, p97/melanotransferrin, PAI-1, platelet-derived growth factor (PDGF), .mu.PA, PRAME, probasin, progenipoietin, prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), prostatic acid phosphatase (PAP), RAGE-1, Rb, RCAS1, SART-1, SSX-family, STAT3, STn, TAG-72, transforming growth factor-alpha (TGF-.alpha.), transforming growth factor-beta (TGF-.beta.), Thymosin-beta-15, tumor necrosis factor-alpha (TNF-.alpha.), TP1, TRP-2, tyrosinase, vascular endothelial growth factor (VEGF), ZAG, p161NK4, and glutathione-S-transferase (GST). 23. The method of claim 11, wherein the immunogenic composition is administered intranasally. 24. A kit comprising the immunogenic composition of claim 1 in a first vial or container for a first administration and in a second vial or container for a second administration. 25. The method of claim 10, wherein the enhanced innate immune response comprises TLR5 activation. 26. The method of claim 25, wherein the enhanced innate immune response further comprises inflammasome activation. 27. The method of claim 19, wherein the Escherichia coli is selected from enterotoxigenic Escherichia coli, enteropathogenic Escherichia coli, and Escherichia coli O157:H7.

Details for Patent 10,512,684

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2034-09-26
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2034-09-26
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2034-09-26
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2034-09-26
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974		2034-09-26
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	03/05/1973		2034-09-26
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2034-09-26